Skip to main content

Advertisement

Table 3 Cox proportional hazards analysis of disease-free survival and overall survival for MA.12 GR methylation study patients

From: Region-specific glucocorticoid receptor promoter methylation has both positive and negative prognostic value in patients with estrogen receptor-positive breast cancer

Characteristic OS DFS
Hazard ratio [95% CI] P Hazard ratio [95% CI] P
Univariate analysis
 GR methylation
  A 0.869 [0.445–1.698] 0.682 0.807 [0.464–1.403] 0.448
  C 0.423 [0.181–0.986] 0.046 0.492 [0.261–0.927] 0.028
  D 0.867 [0.437–1.722] 0.684 1.155 [0.692–1.928] 0.580
  F 0.816 [0.457–1.457] 0.491 0.707 [0.438–1.140] 0.154
  L 1.403 [0.750–2.625] 0.289 1.470 [0.886–2.438] 0.136
  P 1.059 [0.518–2.164] 0.875 1.249 [0.725–2.155] 0.423
  U 1.742 [1.008–3.011] 0.047 1.282 [0.803–2.046] 0.289
  W 1.294 [0.716–2.339] 0.393 1.227 [0.755–1.997] 0.409
 Age   0.089   0.178
  ≤ 45 years 1   1  
  > 45 years 1.577 [0.933–2.666]   1.340 [0.875–20.53]  
 Stage (pathological)   0.8   0.534
  I 1   1  
  II 1.536 [0.380–6.428] 0.536 1.724 [0.543–5.470] 0.355
  III 1.352 [0.247–7.381] 0.728 2.136 [0.566–8.055] 0.262
 Pathological T-stage   0.094   0.261
  T1 1   1  
  T2 1.891 [1.059–3.377] 0.031 1.418 [0.903–2.228] 0.130
  T3/T4 1.310 [0.440–3.898] 0.627 1.552 [0.713–3.379] 0.268
 Nodal status   0.008   0.007
  Node negative 1   1  
  1–3 nodes 1.071 [0.446–2.571] 0.878 1.679 [0.763–3.696] 0.198
  4–9 nodes 1.357 [0.515–3.572] 0.537 1.832 [0.769–4.362] 0.172
  10+ nodes 4.863 [1.565–15.109] 0.006 6.285 [2.106–18.754] 0.001
 Adjuvant chemotherapy   0.31   0.366
  CEF 1   1  
  CMF 0.840 [0.446–1.583] 0.59 0.794 [0.473–1.332] 0.382
  AC 0.570 [0.274–1.186] 0.133 0.662 [0.373–1.174] 0.158
 Treatment   0.914   0.489
  Placebo 1   1  
  Tamoxifen 1.029 [0.609–1.741]   0.860 [0.561–1.318]  
Multivariate analysis
 GR methylation
  C 0.396 [0.164–0.957] 0.04 0.492 [0.252–0.957] 0.037
  U 1.786 [1.025–3.113] 0.041 1.318 [0.822–2.115] 0.252
  1. Multivariate Cox proportional hazards models are adjusted for age, pathological stage, pathological T-stage, nodal status, type of adjuvant chemotherapy, and treatment arm. P values < 0.05 are shown in italics